Qiongding Medical

Qiongding Medical (穹顶医疗, also known as Neurodome, Inc.) is a Xi'an-based hard-tech company developing non-invasive deep-brain neuromodulation devices using Temporal Interference (TI) technology . Founded in 2019 by a Xi'an Jiaotong University neuroscience team, the company builds electrical, ultrasound, and magnetic stimulation products aimed at treating central and peripheral nervous system disorders as well as chronic psychiatric conditions . Its devices are designed to achieve non-invasive, deep-brain, high-precision, multi-target neural stimulation simultaneously—a combination the field has long sought .

FreeS Fund (峰瑞资本) led Qiongding's angel round and has continued to invest through subsequent rounds, including its Pre-A in early 2024 , its A round in March 2025 co-led by Huafang Capital and iFlytek Venture Capital , and its nearly 100 million yuan A+ round in April 2026 led by Mingxi Capital with follow-on from Guanggu Industrial Investment and existing backers . FreeS frames Qiongding as part of its broader brain-computer interface and AI-for-science portfolio, alongside companies like NeuroXess (优脑银河) .